Verified ProfileEN

Hefei Xiaolin Pharmaceutical Co., Ltd.

Order verification — $199

Manufacturing · Proprietary Chinese Medicine Production

Verification dossier

Hefei Xiaolin Pharmaceutical Co., Ltd. is a Chinese company based in Hefei, Anhui. The company operates in the proprietary chinese medicine production sector, within the broader manufacturing industry. Established 2013, the company has been operating for 13 years.

Sinolinks tracks Hefei Xiaolin Pharmaceutical Co., Ltd. as part of our independent verification practice. The full 18-section verification report covers ownership, financial standing, regulatory standing, trade relationships, and operating credentials — reviewed by our Hong Kong-based expert and delivered in 24 hours.

Business scope

Licensed items: Drug import and export; Contract drug manufacturing; Drug wholesale; Drug production. General items: Production of traditional Chinese medicine extracts; Primary processing of edible agricultural products; Production, sales, processing, transportation, storage and other related services of agricultural products; Wholesale of edible agricultural products; Acquisition of primary agricultural products; Food import and export; Cultivation of Chinese medicinal herbs; Vegetable cultivation; Information consulting services (excluding licensed information consulting services); Technical services, development, consulting, exchange, transfer, promotion.

Independent verification

Order the full verified report on this company

An 18-section verification report on this Chinese company, expert-reviewed and delivered in English within 24 hours. We support clients in six languages. HK-entity invoicing.

Order verification — $199

Independent verification

Included in the full report

Full Chinese legal name

Registration identifier

Legal representative & senior officers

Beneficial ownership & equity history

Registered address & operating premises

Capital & recent annual filings

Verified contact channels

Branches, controlled entities & investments

Trademark & patent portfolio

Trade relationships

Regulatory standing review